Background: More and more chronic kidney disease (CKD) patients are accompanied\nwith hyperuricaemia. As is known, hyperuricaemia is an independent\nhazard of both cardiovascular diseases (CVD) and chronic kidney\ndiseases. We aim at identifying Single Nucleotide Polymorphism (SNP) difference\nof hURAT1 (rs7932775) and ABCG2 (rs3825016) on CKD patient\nwith hyperuricemia and/or gout. Methods: All forty-two CKD patients were\ndivided into two groups: hyperuricemia, and control group. 24 hours urine\nsample and serum were prepared for testing biochemistry parameters. The\npolymerase chain reaction-restriction fragment length polymorphism\n(PCR-RFLP) method is used to analyze hURAT1 and ABCG2 single nucleotide\npolymorphisms in different groups. Results: 17 patients have CT SNP of\nhURAT1 (rs7932775) and 13 patients have CT SNP of ABCG2 (rs3825016) in\nhyperuricemia group, while only 5 persons and 6 persons have the same mutations\nin control group respectively. 7 patients have CT SNP of both hURAT1\n(rs7932775) and ABCG2 (rs3825016) in hyperuricemia group, while\nonly 2 persons have the same mutations in control group. CT mutation rates\nof hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group\nwere 60.7% (17/28) and 50% (13/28) respectively, higher than that of control\ngroup (35.7% (5/14) and 42.8% (6/14)). What is more, Double SNP mutations\nin both hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia\ngroup were 25% (7/28), higher than that of control group (14.2%, 2/14).\nConclusion: There are higher mutation rates of CT SNP in hURAT1\n(rs7932775) and/or ABCG2 (rs3825016) in hyperuricemia group. We can\nconclude that hyperuricemia is a high risk factor in progress of CKD, which is necessary to take measures of decreasing serum uric acid to delay CKD\nprogress.
Loading....